Dacomitinib/Dacomitinib manufacturer and original drug information

Dacomitinib (Dacomitinib) is a second-generation irreversible EGFR tyrosine kinase inhibitor that is mainly used to treat non-small cell lung cancer patients with sensitive mutations in the EGFR gene. The R&D and production of this drug are completed by Pfizer, an internationally renowned pharmaceutical company, and it is an important representative product of Pfizer in the field of targeted therapy. As an original research manufacturer, Pfizer has a complete R&D system and global marketing experience, allowing dacomitinib to quickly enter major markets and gain high recognition.

In China, Pfizer's original drug dacomitinib has been officially launched and included in the Category B scope of the National Reimbursement Directory, significantly reducing patients' medication burden. At present, the common specification in China is 15mg*30 tablets, and the price of each box is about more than 1,000 yuan after medical insurance reimbursement, which greatly improves the accessibility of the drug. Compared with many new targeted drugs that are not included in medical insurance, dacomitinib’s medical insurance coverage has greatly increased its use rate in China.

In overseas markets, especially in Europe, the price of dacomitinib’s original drug is relatively high. For example, the price of a box of 45mg*30 tablets may exceed RMB 20,000. The specific price will be affected by local medical system policies, market supply, and exchange rate fluctuations. This large price difference reflects the differences in drug pricing systems in the global market, and also prompts patients to weigh the financial burden and the formality of the drug source when choosing a drug purchase channel.

In general, dacomitinib is developed and produced by Pfizer Pharmaceuticals. The quality and efficacy of the original drug are guaranteed. The medical insurance support after domestic launch provides a more cost-effective treatment option for the majority of EGFR mutant non-small cell lung cancer patients. At the same time, its global supply also brings more accessibility to patients in different countries and regions.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro